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Abstract
Background: The efficacy of intravenous quinine, which is the mainstay for treating severe malaria
in children, is decreasing in South East Asia and Africa. Artemisinin derivatives are a potential
alternative to quinine. However, their efficacy compared to quinine in treating severe malaria in
children is not clearly understood. The objective of this review was to assess the efficacy of
parenteral artemisinin derivatives versus parenteral quinine in treating severe malaria in children.
Methods: All randomized controlled studies comparing parenteral artemisinin derivatives with
parenteral quinine in treating severe malaria in children were included in the review. Data bases
searched were: The Cochrane Central Register of Controlled Trials (The Cochrane Library Issue
4, 2007), MEDLINE (1966 to February 2008), EMBASE (1980 to February 2008), and LILACS (1982
to February 2008). Dichotomous variables were compared using risk ratios (RR) and the
continuous data using weighted mean difference (WMD).
Results:  Twelve trials were included (1,524 subjects). There was no difference in mortality
between artemisinin derivatives and quinine (RR = 0.90, 95% CI 0.73 to 1.12). The artemisinin
derivatives resolved coma faster than quinine (WMD = -4.61, 95% CI: -7.21 to -2.00, fixed effect
model), but when trials with adequate concealment only were considered this differences
disappeared. There was no statistically significant difference between the two groups in parasite
clearance time, fever clearance time, incidence of neurological sequelae and 28th day cure rate. One
trial reported significantly more local reactions at the injection site with intramuscular quinine
compared to artemether. None of the trials was adequately powered to demonstrate equivalence.
Conclusion:  There was no evidence that treatment of children with severe malaria with
parenteral artemisinin derivatives was associated with lower mortality or long-term morbidity
compared to parenteral quinine. Future studies require adequately powered equivalence trial
design to decide whether both drugs are equally effective.
Background
Malaria remains a major public health problem globally.
It is estimated that each year there are about 350–500 mil-
lion clinical cases of malaria, which result in more than 1
million deaths [1]. About 80% of these deaths occur in
sub-Saharan Africa among children aged below five years
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[1,2]. Therefore, children are the population group with
the highest malaria case fatality rate.
Over the years quinine has been the mainstay for treating
severe malaria in children, but despite its high efficacy the
case fatality rate for severe malaria in children can be as
high as 40% [3]. Additionally, in recent years there have
been concerns that the efficacy of quinine is declining in
some parts of South East Asia and quinine resistance has
been documented in Africa [4-7]. This led to the launch of
a series of trials to find drugs that are suitable alternatives
to quinine. The studies focused on artemisinin derivatives
[8-19]; a group of drugs with no known Plasmodium falci-
parum  resistance and which act faster than all known
malaria drugs [20]. Pharmacokinetic studies in children
with severe P. falciparum malaria, particularly with meta-
bolic acidosis, however, showed variable and unpredicta-
ble absorption of artemether after intramuscular injection
a problem not encountered with intramuscular quinine
[21,22].
Because the findings from individual studies were incon-
clusive, two reviews have been conducted to clarify the
efficacy of artemisinin derivatives versus existing drugs
used for severe malaria [23,24]. The first looked at the effi-
cacy of artemether versus quinine in treating severe
malaria [23] and the second evaluated the efficacy of
artemisinin derivatives versus standard drugs used for
treating severe malaria (e.g. quinine, chloroquine, and
others)[24]. The first review showed that there was no sig-
nificant difference between artemether and quinine in
mortality rate (OR = 0.76, 95% CI 0.5 to 1.14, random
effects model)[23]. The second review showed that artem-
isinin derivatives reduced mortality compared to quinine,
but the difference was marginal when data from high
quality trials only were considered (OR = 0.72, 95% CI
0.54 to 0.96, random effects model) [24]. While these
findings seem to suggest that artemisinin derivatives are
either equal to, or have marginal advantage over quinine
in mortality reduction, both reviews did not consider the
efficacy of the drugs on severe malaria in children sepa-
rately. They pooled data from adults and children. There-
fore, it is difficult to apply the findings directly to
children; the group, which possibly respond to malaria
drugs differently from adults. The objective of this review
was to assess the available evidence on the efficacy of
parenteral artemisinin derivatives versus quinine in treat-
ing severe malaria in children.
Methods
Studies were considered for inclusion in the review if they
were randomized controlled trials comparing one
parenteral artemisinin derivative (artemether, β-arteether/
artemotil or artesunate) with parenteral quinine in chil-
dren aged between 0 to 16 years or if trials stated that they
included children only. The participants had to have
severe malaria as defined by the World Health Organiza-
tion (WHO) [25]. Trials including both adults and chil-
dren were excluded. Studies were not considered if: an
artemisinin derivative was combined with another anti-
malarial and compared with quinine, comparison was
between two or more artemisinin derivatives or compari-
son was between regimens of one artemisinin derivative.
The review's primary outcome was mortality while para-
site clearance time (PCT), fever clearance time (FCT),
coma resolution time (CRT), incidence of neurological
sequelae, 28th  day cure rate and incidence of adverse
effects were the secondary outcomes.
Electronic databases and other sources were used to search
for studies to include in the review. The electronic data-
bases searched were: The Cochrane Central Register of
Controlled Trials (The Cochrane Library Issue 4, 2007),
MEDLINE (1966 to February 2008), EMBASE (1980 to
February 2008), and LILACS (1982 to February 2008).
With the support of a Cochrane information specialist a
comprehensive search strategy for each database was
developed using both controlled vocabulary terms and
free text words to ensure that all potential articles regard-
less of language or publication status were retrieved. The
following key words were used: artemisinins, dihydroar-
temisinins, artemether, artesunate, β-arteether, artemotil,
quinine, malaria, "cerebral, malaria", "severe malaria"
complicated malaria, "malaria, falciparum", and rand-
omized controlled trials. Other sources searched
included: The proceedings of the 11th annual scientific
conference (with seminar on malaria) of the Tanzania
National Institute for Medical Research conducted
between 4th to 7th February 1993, in Arusha, Tanzania. In
addition, 26 malaria researchers across Africa, Asia,
Europe and America were contacted to find out if they had
any information on published, unpublished or ongoing
trials for possible inclusion in the review. The reference
lists of the retrieved articles were also searched for more
articles.
After the literature search was completed the results were
sorted to include abstracts, which had the potential of
being included in the review. Complete articles of the
potential abstracts were either retrieved or ordered. If a
trial was published more than once, only one publication
was presented for assessment and if an interim analysis of
a particular major trial was published, only the final pub-
lication was presented for assessment. GP and AD
assessed the articles for their suitability for inclusion in
the review.
Then all included studies were assessed by GP and AD for
their quality in design and conduct. Generation of alloca-
tion sequence, allocation concealment, blinding and loss
to follow up, were used to assess the quality of studies as
recommended previously [26].Malaria Journal 2008, 7:210 http://www.malariajournal.com/content/7/1/210
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GP extracted data using special forms, and then it was ana-
lysed using STATA version 8.2. Binary outcomes were
compared by risk ratio (RR) and continuous outcomes by
weighted mean difference (WMD). The 95% confidence
interval (CI) was used and p value < 0.05 was assumed to
be showing a statistically significant difference.
To assess heterogeneity, forest plots were visually exam-
ined (for overlapping confidence intervals) and the chi-
squared test for heterogeneity with p value < 0.05 was
assumed to be showing significant heterogeneity among
trials. The fixed effect model was employed in pooling
data where there was no evidence of heterogeneity and
where there was evidence of heterogeneity, the random
effects model was used instead. Because there was signifi-
cant heterogeneity in parasite clearance time, fever clear-
ance time and 28th day cure rate; it was decided to explore
the study setting (Asian versus non-Asian studies) as a
possible source of heterogeneity. The rationale for choos-
ing this characteristic was that in Asia, evidence suggested
that the level of quinine resistance was higher than on
other continents and therefore artemisinin derivatives
were likely to be comparably more efficacious in Asia than
on other continents; a situation that could have intro-
duced heterogeneity in pooled data. Also sensitivity anal-
ysis based on adequacy of concealment was carried out for
all outcomes. Data on adverse effects were summarized.
Results
Description of studies
Twelve randomized controlled trials involving 1524 chil-
dren met the inclusion criteria and were included in the
review [8-19]. Details of these studies are found in Table
1. They were conducted in nine countries i.e. Nigeria,
Kenya, Zambia, Cameroon, Malawi, Gambia, Sudan,
India and Vietnam and published between 1993 and
2003. Trials participants were children aged from 0 to 15
years, inclusion criterion in nine trials was cerebral
malaria[8-10,12-16,18] and in 3 trials any form of severe
malaria [11,17,19]. Nine trials [8-10,12-14,17-19] used
intramuscular artemether while one trial used intramus-
cular artesunate [11]. Two trials used intramuscular arte-
motil/β-arteether [15,16]. The duration of artemisinin
derivatives treatment ranged from 3–6 days while that for
quinine ranged from 1 to 7 days. In one trial, quinine was
administered intramuscularly [10] and in the rest it was
administered intravenously [8,9,11-19].
Methodological quality of included trials
Methods used in generation of allocation sequence were
adequate in six trials [9,10,12,14-16] and were not clear in
the remaining trials [8,11,13,17-19]. Eight trials had ade-
quate allocation concealment [9-12,14-17] and thus they
were of high quality. In one trial the methods used to con-
ceal the allocation were inadequate [19] and in the other
three the allocation concealment methods used were
unclear [8,13,18]. In three trials, the procedures were
described as open [8,9,12]. In four trials, it was stated that
there was blinding of microscopists [10,15,17,19]. In the
remaining trials there was no description with regard to
blinding and indeed trial procedures precluded any blind-
ing.
In three trials, there were no reports of loss to follow up or
exclusion from analysis for the primary outcome
[13,17,19]. In seven other trials, loss to follow-up or
exclusion from analysis was below 10% [8,11,10,14-
16,18]. A trial in Malawi excluded from analysis 10.3%
(19/183) of study participants [12] and another trial in
Kenya excluded from analysis 20% (40/200) of partici-
pants initially included in the study [9]. And only three
trials described how the sample size required to detect sta-
tistical significant differences in outcomes among treat-
ment groups was achieved [10,12,15].
Mortality
Nine trials [8-12,14-16,19] were designed to measure
mortality rate with artemisinin derivatives and quinine as
a primary outcome, whilst three trials were not designed
to measure mortality as a primary outcome but did report
the mortality rates with the two drug groups [13,17,18].
Nine trials showed that artemisinin derivatives had lower
mortality than quinine, but none of these results were sta-
tistically significant [8,10-14,16,17,19]. Two other trials
showed that quinine had a reduced mortality compared
to artemisinin derivatives, but the differences were not sta-
tistically significant [9,15]. In one trial, a significance test
for the difference in mortality rates in the two groups was
not stated, but the rates looked comparable (7.8% for
artemether and 5% for quinine)[18]. The pooled analysis
showed that, compared to quinine, administration of
artemisinin derivatives in children with severe malaria
was not associated with a reduced mortality(RR = 0.90,
95%CI: 0.73 to 1.12, fixed effect model)(Figure 1). Sub-
group analysis showed that, of the three artemisinin drugs
studied i.e. β-arteether, artemether and artesunate none
was better than quinine in mortality reduction (RR = 0.75,
95%CI: 0.43 to 1.30, fixed effect model), (RR = 0.94,
95%CI: 0.74 to 1.19, fixed effect model) and (RR = 0.76,
95%CI: 0.22 to 2.59, fixed effect model) respectively (Fig-
ure 2). Sensitivity analysis based on adequacy of conceal-
ment, showed that there was no statistical difference in
mortality between artemisinin derivatives and quinine in
studies with adequacy of concealment (RR = 0.92, 95%CI:
0.73 to 1.15, fixed effect model).
Parasite clearance time
Six studies showed no statistically significant difference in
mean parasite clearance times between artemisinin deriv-
atives and quinine [8,14-18], whilst one study showedMalaria Journal 2008, 7:210 http://www.malariajournal.com/content/7/1/210
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Table 1: Trial participants, interventions and outcomes
Reference Participants Interventions 
(drugs, route of administration and 
treatment duration)
Outcomes
[8] 54 children aged 1 to 5 
years in Nigeria
(1) IM Artemether 3.2 mg/kg in the first day, then 
1.6 mg/kg for 4 days
Mortality, parasite clearance time, fever clearance 
time, coma resolution time, 28th day cure rate, 
adverse effects & neurological sequelae
(2) IV Quinine 20 mg/kg loading dose then 10 mg 8 
hrly for 7 days. This was changed to oral dose 
when patient was able to drink
[9] 160 children aged 5 
month to 12 years in 
Kenya
(1) IM Artemether 3.2 mg/kg in the first day, then 
1.6 mg/kg for 2 days. One dose of SP was given 
after parasite clearance.
Mortality, parasite clearance time, fever clearance 
time, coma resolution time, adverse effects & 
neurological sequelae
(2) IV Quinine 20 mg/kg loading dose then 10 mg 8 
hrly for at least 3 days. Then one dose of SP was 
given after parasites clearance and when the 
patient was able to drink
[10] 576 children aged 1 to 9 
years in Gambia
(1) IM Artemether 3.2 mg/kg in the first day, then 
1.6 mg/kg for 3 days
Mortality, parasite clearance time, fever clearance 
time, coma resolution time, 28th day cure rate, 
adverse effects & neurological sequelae
(2) IM Quinine 20 mg/kg loading dose then 10 mg 
8 hrly for 5 days. This was changed to oral dose 
when the patient was able to drink
[11] 72 children aged 3 months 
to 14 years in Vietnam
(1) IM Artesunate 3 mg/kg initially and 2 mg/kg at 
12, 24,48 and 72 hrs, followed by oral mefloquine 
15 mg/kg at 96 hours
Mortality, parasite clearance time, fever clearance 
time, coma resolution time, duration of hospital 
stay, adverse effects & neurological sequelae
(2) IM Quinine 20 mg/kg loading dose then 10 mg 
8 hrly for 7 days, followed by single dose of 
pyrimethamine/sulfadoxine on day 7
[12] 164 children in Malawi 
(age range not stated)
(1) IM Artemether 3.2 mg/kg in the first day, then 
1.6 mg/kg for 4 days
Mortality, parasite clearance time, fever clearance 
time, coma resolution time, coma resolution time, 
28th day cure rate, adverse effects & neurological 
sequelae
(2) IV Quinine(20 mg/kg loading dose then 10 mg 
8 hrly for 7 days, changed to oral dose when 
patient was able to drink
[13] 37 children in Nigeria 
(age range not stated)
(1) IM Artemether 3.2 mg/kg starting dose, then 
1.6 mg/kg 12 hours later, then 1.6 mg/kg per day 
for 2 days
Mortality, percentage of children with parasites 
clearance at day 7, fever clearance time, coma 
resolution time & neurologic sequelae
(2) IV Quinine 10 mg/kg initial dose then 10 mg 8 
hrly for 7 days, changed to oral dose when patient 
was able to drink
[14] 103 children aged 1 to 5 
years in Nigeria
(1) IM Artemether 3.2 mg/kg in the first day, then 
1.6 mg/kg for 4 days
Mortality, parasite clearance time, fever clearance 
time, coma resolution time, 28th day cure rate & 
neurological sequelae
(2) IV Quinine 20 mg/kg loading dose then 10 mg 8 
hrly for 7 days, changed to oral dose when patient 
was able to drink
[15] 92 children aged 0–10 
years in Zambia
(1) IM β-Arteether 3.2 mg/kg in the first day, then 
1.6 mg/kg for next 4 days
Mortality, parasite clearance time, fever clearance 
time, coma resolution time, adverse effects & 
neurological sequelae
(2) IV Quinine (20 mg/kg loading dose then 10 mg 
8 hrly for 7 days, changed to oral dose when 
patient was able to drinkMalaria Journal 2008, 7:210 http://www.malariajournal.com/content/7/1/210
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that mean parasite clearance time was shorter in the
artemisinin derivative than quinine[19]. Four studies, all
with adequate concealment, which reported parasite
clearance times as median, found that artemisinin deriva-
tives cleared parasites faster than quinine [9-12]. One trial
showed that the percentage of children with parasite clear-
ance at day 7 was significantly higher in the quinine group
than in the artemether group [13]. Analysis based on type
of drug used showed that of the two drug groups which
reported parasite clearance time as mean i.e. β-arteether
and artemether none of these cleared parasites faster than
quinine.
Overall, pooled analysis showed that artemisinin deriva-
tives did not clear parasites faster than quinine (WMD = -
3.82, 95%CI: -8.73 to 1.10, random effect model). (Figure
3). Also, sensitivity analysis showed that artemisinin
derivatives did not clear parasites faster in trials, which
were adequately concealed (-1.49, 95% CI -7.36 to 4.39,
random effect model). Subgroup analysis revealed hetero-
geneity between Asian and African studies and showed
parasite clearance time was shorter for artemisinin deriva-
tives in Asian studies, but not in African studies ((WMD =
-11.0, 95% CI: -14.92 to -7.08, random effect model) and
[16] 102 children aged 0–10 
years in Cameroon
(1) IM β-Arteether 3.2 mg/kg in the first day, then 
1.6 mg/kg for 4 days
Mortality, parasite clearance time, fever clearance 
time, coma resolution time, adverse effects, 28th 
cure rate & neurological sequelae
(2) IV Quinine 20 mg/kg loading dose then 10 mg 8 
hrly for 7 days, changed to oral dose when patient 
was able to drink
[17] 41 children in Sudan 
(age range not stated)
(1) IM Artemether 3.2 mg/kg in the first day, then 
1.6 mg/kg for t 4 days
Mortality, parasite clearance time, fever clearance 
time, coma resolution time & adverse effects
(2) IV Quinine 20 mg/kg loading dose then 10 mg 8 
hrly for 7 days, changed to oral dose when patient 
was able to drink
[18] 77 children aged 3 months 
to 15 years in Sudan
(1) IM Artemether 1.6 mg/kg, repeated after 12 
hrs, then daily for 4 days
Mortality, parasite clearance time, fever clearance 
time, coma resolution time & 28th day cure rate
(2) IV Quinine 10 mg/kg 8 hrly for 7 days, changed 
to oral dose when patient was able to drink
[19] 46 children aged 0–14 
years from India
(1) IM Artemether 3.2 mg/kg in the first day, then 
1.6 mg/kg for 5 days
Mortality, parasite clearance time, fever clearance 
time, coma resolution time & adverse effects
(2) IV Quinine (20 mg/kg loading dose then 10 mg 
8 hrly for 7 days, changed to oral dose when 
patient was able to drink
Table 1: Trial participants, interventions and outcomes (Continued)
Meta-analysis of effect of artemisinin derivatives versus qui- nine on mortality (fixed effect model) Figure 1
Meta-analysis of effect of artemisinin derivatives ver-
sus quinine on mortality (fixed effect model). Weight 
of study was expressed by size of square.
Risk ratio
Favours artemisinins Favours quinine
.015050 1 66.4433
Study
Risk ratio
(95% CI) % Weight
[8] 0.58 ( 0.16, 2.08) 3.9
[9] 1.79 ( 0.83, 3.89) 6.2
[10] 0.95 ( 0.69, 1.31) 43.3
[11] 0.76 ( 0.22, 2.59) 3.6
[12] 0.81 ( 0.37, 1.78) 8.5
[13] 0.53 ( 0.05, 5.33) 1.4
[14] 0.71 ( 0.36, 1.42) 10.3
[15] 1.02 ( 0.46, 2.27) 6.6
[16] 0.57 ( 0.26, 1.24) 9.8
[17] 0.35 ( 0.02, 8.10) 1.0
[18] 1.54 ( 0.27, 8.71) 1.4
[19] 0.83 ( 0.30, 2.35) 4.2
Overall 0.90 ( 0.73, 1.12) 100.0
Subgroup meta-analysis of effect of β-arteether, artemether  and artesunate versus quinine on mortality (fixed effect  model) Figure 2
Subgroup meta-analysis of effect of β-arteether, arte-
mether and artesunate versus quinine on mortality 
(fixed effect model). Weight of study was expressed by 
size of square.
Risk ratio
Favours artemisinins Favours quinine
.015050 1 66.4433
Study
Risk ratio
(95% CI) % Weight
Arteether
[15] 1.02 ( 0.46, 2.27) 6.6
[16] 0.57 ( 0.26, 1.24) 9.8
Subtotal 0.75 ( 0.43, 1.30) 16.3
Artemether
[8] 0.58 ( 0.16, 2.08) 3.9
[9] 1.79 ( 0.83, 3.89) 6.2
[10] 0.95 ( 0.69, 1.31) 43.3
[12] 0.81 ( 0.37, 1.78) 8.5
[13] 0.53 ( 0.05, 5.33) 1.4
[14] 0.71 ( 0.36, 1.42) 10.3
[17] 0.35 ( 0.02, 8.10) 1.0
[18] 1.54 ( 0.27, 8.71) 1.4
[19] 0.83 ( 0.30, 2.35) 4.2
Subtotal 0.94 ( 0.74, 1.19) 80.1
Artesunate
[11] 0.76 ( 0.22, 2.59) 3.6
Subtotal 0.76 ( 0.22, 2.59) 3.6
Overall 0.90 ( 0.73, 1.12) 100.0Malaria Journal 2008, 7:210 http://www.malariajournal.com/content/7/1/210
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(WMD = -2.46, 95% CI: -6.43 to 1.51, random effect
model) respectively).
Fever clearance time
Of the eight studies which reported fever clearance times,
six showed no statistical significant difference in fever
clearance times among the two interventions [8,14-
16,18,19], while two studies showed that artemisinin
derivatives cleared fever faster than quinine[13,17]. Of the
four trials which reported fever clearance times as median,
three showed no statistical difference in clearance times of
the two drug groups [9-11] and one reported that arte-
mether cleared fever faster than quinine [12]. Analysis by
the type of artemisinin used showed that neither β-
arteether nor artemether cleared fever faster than quinine.
The pooled analysis showed that artemisinin derivatives
did not clear fever faster than quinine (WMD = -2.58,
95%CI: -9.53 to 4.38, random effect model)(Figure 4).
Analysis among trials with adequacy of concealment, also
showed no statistical significant difference between
artemisinin derivatives and quinine (WMD = 4.60,95%CI
-6.61 to 15.80, random effect model). Subgroup analysis
revealed no evidence of heterogeneity between Asian and
African studies ((WMD = -1.40, 95%CI: -6.34 to 3.54, ran-
dom effect model) and (WMD = -2.64, 95%CI: -11.76 to
6.47, random effect model) respectively).
Coma resolution time
Among eight studies which reported mean coma resolu-
tion times, six trials showed no statistically significant dif-
ference between artemisinin derivatives and quinine
[8,14-18], whilst the other two trials showed that coma
resolution time was significantly shorter in the artemisi-
nin group compared to the quinine group [13,19]. Among
four trials which reported median coma resolution times
only one trial showed that quinine resolved coma faster
than the artemether [10], others showed there were no
differences[9,11,12]. Analysis by type of artemisinin drug
used showed that artemether, but not β-arteether resolved
coma faster than quinine.
Overall pooled analysis showed that artemisinin deriva-
tives resolved coma faster than quinine (WMD = -4.61,
95% CI: -7.21 to -2.00, fixed effect model (Figure 5). This
superiority of artemisinins over quinine was no longer sig-
nificant when only trials with adequate allocation con-
cealment were considered (-3.00, 95% CI -8.54 to 2.53,
fixed effect model).
Meta-analysis of effect of artemisinin derivatives versus qui- nine on parasites clearance time (random effect model) Figure 3
Meta-analysis of effect of artemisinin derivatives ver-
sus quinine on parasites clearance time (random 
effect model). Weight of study was expressed by size of 
square.
Mean difference
Favours artemisinins Favours quinine
-16.658 0 16.6588
Study
Mean difference
(95% CI) % Weight
[8] 2.10 (-12.46, 16.66) 8.0
[14] 2.50 (-8.47, 13.47) 11.6
[15] -4.00 (-15.67, 7.67) 10.7
[16] 5.60 (-4.87, 16.07) 12.2
[17] -6.40 (-12.85, 0.05) 18.5
[18] -5.00 (-13.01, 3.01) 15.8
[19] -11.00 (-14.92,-7.08) 23.2
Overall -3.82 (-8.73, 1.10) 100.0
Meta-analysis of effect of artemisinin derivatives versus qui- nine on fever clearance time (random effect model) Figure 4
Meta-analysis of effect of artemisinin derivatives ver-
sus quinine on fever clearance time (random effect 
model). Weight of study was expressed by size of square.
Mean difference
Favours artemisinins Favours quinine
-34.190 0 34.1901
Study
Mean difference
(95% CI) % Weight
[8] -11.10 (-25.04, 2.84) 10.6
[13] -18.60 (-28.54,-8.66) 13.4
[14] -6.70 (-18.32, 4.92) 12.1
[15] 17.00 (-0.19, 34.19) 8.7
[16] -2.80 (-16.80, 11.20) 10.5
[17] 12.50 ( 2.67, 22.33) 13.4
[18] -5.00 (-13.38, 3.38) 14.5
[19] -1.40 (-6.34, 3.54) 16.8
Overall -2.58 (-9.53, 4.38) 100.0
Meta-analysis of effect of artemisinin derivatives versus qui- nine on coma resolution time (fixed effect model) Figure 5
Meta-analysis of effect of artemisinin derivatives ver-
sus quinine on coma resolution time (fixed effect 
model). Weight of study was expressed by size of square.
Mean difference
Favours artemisinins Favours quinine
-40.593 0 40.5937
Study
Mean difference
(95% CI) % Weight
[8] 3.40 (-14.23, 21.03) 2.2
[13] -4.90 (-9.29,-0.51) 35.2
[14] -7.30 (-20.54, 5.94) 3.9
[15] 17.00 (-6.59, 40.59) 1.2
[16] 4.50 (-6.38, 15.38) 5.7
[17] -7.50 (-15.25, 0.25) 11.3
[18] -5.00 (-12.02, 2.02) 13.8
[19] -6.00 (-11.04,-0.96) 26.7
Overall -4.61 (-7.21,-2.00) 100.0Malaria Journal 2008, 7:210 http://www.malariajournal.com/content/7/1/210
Page 7 of 9
(page number not for citation purposes)
Incidence of neurological sequelae
Ten trials reported or had data on incidence of neurologi-
cal sequelae at discharge or at day seven [8-16,18]. The
sequelae reported included motor deficits, severe hypoto-
nia, aphasia, abnormality in gait, cortical-deafness, blind-
ness, learning difficulties, hallucinations, hemiplegia and
quadriparesis. Two other trials reported that neurological
sequelae had not been observed during follow up [17,19].
Of the three artemisinin drugs studied i.e. β-arteether,
artemether and artesunate none had less neurological
sequelae than quinine. When the data from all ten studies
were pooled together the results showed that there was no
statistical difference among the two groups for this out-
come (RR = 0.96, 95%CI: 0.75 to 1.22, fixed effect
model)(Figure 6). When adequately concealed trials only
were considered the findings were similar (RR = 0.93,
95%CI: 0.72 to 1.20, fixed effect model)
28th day cure rate
Six trials reported or had data that could be extracted on
28th  day cure rates [8,10,12,14,16,18]. In these trials,
almost all survivors were followed for 28 days and none
of trials used molecular methods to differentiate between
recrudescence and re-infection. In one trial the cure rate
was 100% for the two arms of the trial (18). In one other
trial participants received sulphadoxine/pyrimethamine
(SP) before they were discharged from hospital in year
two and year three of the trial [10]. In this trial, recrudes-
cence rates in the first year were not statistically different
among the two groups and in the following two years, the
rates were similar (10.6% and 9.4% respectively). In the
other two trials, children received SP after parasites were
cleared [9,12]. In these three trials, which used SP after
coma resolution, parasite clearance or at discharge, the cri-
terion for its use was the same among trials' interventions.
In two trials one child each, in the artemether groups,
developed parasitaemia on day 14 [8,14]. These children
were treated successfully. Analysis by the type of artemisi-
nin used showed that neither β-arteether nor artemether
had higher cure rate than quinine. When the results were
pooled, it was shown that there was no statistical differ-
ence in cure rates between the two drug groups (R R =
0.99, 95%CI: 0.92 to 1.06, random effect model)(Figure
7). Results were similar when adequately concealed trials
only were considered. Subgroup analysis to explore heter-
ogeneity between Asian and African studies was not pos-
sible because the data available for pooling was from
Africa studies only.
Incidence of adverse effects
The trials included in this review were not designed to
evaluate differences in adverse effects amongst the two
groups. 11 trials commented on adverse effects. Trials,
which reported this outcome, reported it either incom-
pletely or in a way that hindered thorough comparison
among the interventions. Therefore only a descriptive nar-
rative of the data is given. One trial report contained a
detailed listing of adverse effects in a trial comparing arte-
motil (β-arteether) with quinine as assessed twice daily for
seven days and then weekly for another three weeks. It
showed that there was no difference in weakness, aphasia/
speech disorder, deafness, fevers/rigors, anorexia, nausea,
vomiting, diarrhoea, cough, pneumonia, conjunctivitis
between groups [15].
Meta-analysis of effect of artemisinin derivatives versus qui- nine on incidence of neurological sequelae (fixed effect  model) Figure 6
Meta-analysis of effect of artemisinin derivatives ver-
sus quinine on incidence of neurological sequelae 
(fixed effect model). Weight of study was expressed by 
size of square.
Risk ratio
Favours artemisinins Favours quinine
.014808 1 67.5267
Study
Risk ratio
(95% CI) % Weight
[8] 1.57 ( 0.29, 8.51) 1.9
[9] 0.76 ( 0.27, 2.14) 7.3
[10] 0.83 ( 0.59, 1.16) 56.2
[11] 2.84 ( 0.12, 67.53) 0.5
[12] 1.51 ( 0.74, 3.10) 10.1
[13] 1.06 ( 0.17, 6.72) 1.9
[14] 0.58 ( 0.20, 1.67) 7.6
[15] 1.08 ( 0.60, 1.96) 12.6
[16] 1.72 ( 0.16, 18.22) 1.1
[18] 2.05 ( 0.19, 21.71) 1.0
Overall 0.96 ( 0.75, 1.22) 100.0
Meta-analysis of effect of artemisinin derivatives versus qui- nine on 28th day cure rates (random effect model) Figure 7
Meta-analysis of effect of artemisinin derivatives ver-
sus quinine on 28th day cure rates (random effect 
model). Weight of study was expressed by size of square.
Risk ratio
Favours artemisinins Favours quinine
.656078 1 1.52420
Study
Risk ratio
(95% CI) % Weight
[8] 0.95 ( 0.84, 1.08) 17.8
[10] 0.91 ( 0.83, 1.00) 22.5
[12] 1.07 ( 0.99, 1.15) 26.5
[14] 0.98 ( 0.92, 1.05) 28.4
[16] 1.13 ( 0.83, 1.52) 4.9
[18] (Excluded)
Overall 0.99 ( 0.92, 1.06) 100.0Malaria Journal 2008, 7:210 http://www.malariajournal.com/content/7/1/210
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Another trial comparing artesunate with quinine found
that patients on quinine suffered significantly more often
from vomiting (30%), nausea (50%), headaches (40%)
and tinnitus (20%) than patients on artesunate who had
none of these adverse effects [18]. One trial reported on a
fatal complication, which may have represented an
adverse effect: A case of black water fever in a patient on
quinine [16]. One trial reported that the group receiving
artesunate had significantly lower reticulocytes counts
compared to quinine by day 5 of treatment, but the differ-
ence was no longer significant by day of discharge [11].
Another trial reported one case of hypoglycaemia among
the quinine group [17]. Four trials reported on results of
ECG monitoring in 341 patients. One trial reported that
patients treated with artemether showed a significant pro-
longation of the QTc interval significantly more fre-
quently (20/82) than in the group treated with quinine
(5/80) [9]. Another study found no significant difference
in QTc intervals between groups [12] and there were more
patients with prolonged QTc interval in the group on qui-
nine. Neither of these studies demonstrated arrhythmias.
Supraventricular tachycardia was noted in two patients on
quinine in another study [8]. Another study reported no
cardiac event in either artesunate or quinine patient after
24 hrs of cardiac monitoring from admission[11].
Another trial reported that local reactions at the site of
injection were more common in the quinine group
(5.9%) than in the artemether group (0.7%) with abscess
formation requiring drainage in 5/288 patients in the qui-
nine and 1/288 in the artemether group [10].
Discussion
This review suggests that artemisinin derivatives are not
superior to quinine in preventing mortality from severe
malaria in childhood. It also showed that though CRT was
shorter with artemisinin derivatives, this difference was
no longer significant when high quality studies were con-
sidered, indicating that the overall pooled results may
have been biased by results from low quality trials. Other
outcomes i.e. PCT, FCT, incidence of neurological seque-
lae and 28th cure rates showed no difference among the
two drug groups. Though data on adverse effects were
inadequate, administration of intramuscular quinine was
characterized by more local reactions at the injection site
compared to artemether. In one study, it was found that
compared to quinine, administration of intramuscular
artesunate led to signs of transient bone marrow depres-
sion.
Subgroup analysis of the individual artemisinins showed
that none of the drug studied (i.e. β-arteether, artesunate
and artemether) in this review had lower mortality rate
than quinine. It is important to note that despite this con-
clusion there were only two studies with a total of 194
children that compared β-arteether versus quinine, and
only one study with 72 children that compared artesunate
versus quinine, the number of subjects in these two drugs
is too small to make a conclusion on their efficacy com-
pared to quinine in terms of mortality. In contrast there
were nine studies with 1258 children that compared arte-
mether versus quinine and found it to be not different in
effect on mortality. Previous reviews also came to a similar
conclusion [23,24]. A more recent review found a reduc-
tion in mortality in patients treated with artesunate [27].
A reason for the lack of mortality reduction in children
treated with intramuscular artemether may be its slow and
erratic absorption thus failing to reverse and prevent path-
ological processes leading to death in severe malaria in
children. It is now known that parenteral artesunate may
be faster absorbed after intramuscular injection than arte-
mether and a study in Asia showed that it may reduce
mortality in Asian adults [28]. An interest in artesunate as
possible alternative to quinine led to the implementation
of a big multicentre randomized study comparing injecta-
ble artesunate and quinine in children with severe falci-
parum malaria in Africa. When this study is completed it
will be known whether artesunate is better than quinine
in African children. The superiority of artemisinin deriva-
tives in parasite clearance in trials conducted in India may
be an indicator of reduced sensitivity of Asian P. falci-
parum strains to quinine. Future reviews need to include
subgroup analyses for Asian and African regions sepa-
rately as long as quinine resistance is sporadic in Africa.
Based on efficacy; this review does not justify a replace-
ment of intravenous quinine by artemisinin derivatives
when treating children with severe malaria in Africa and
Asian countries where P. falciparum strains are known to
be sensitive to quinine. However, since the efficacies
between the two groups of drugs are comparable decision
to replace quinine may be taken if other factors such as
costs, user preference and logistics are taken into consid-
eration.
Given the results of this review studies comparing artem-
isinin derivatives with quinine in treatment of severe
malaria in children need to follow equivalence trial
design. A sample size calculation for an equivalence trial
taking mortality as a primary outcome, with a difference
in mortality of five percent taken as range of equivalence
and 85% survival as expected with standard quinine treat-
ment of cerebral malaria, a sample size of at least 1071 in
each treatment group would be required to demonstrate
equivalence with a power of 80% with a two sided confi-
dence interval of 95% for the difference in mortality [29].
For coma recovery time with a difference in coma recovery
time of four hours as range of equivalence and 12 hours
as standard deviation with 80% power and 95% confi-
dence interval for the difference at least 189 participants
would be required in each group to demonstrate equiva-Malaria Journal 2008, 7:210 http://www.malariajournal.com/content/7/1/210
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lence. This means none of the trials reviewed was suffi-
ciently powered to demonstrate equivalence and exclude
clinically significant differences in these key outcomes.
Adequately sized trials investigating the main outcomes
mortality, coma recovery time and neurological sequelae
need to be conducted in the future.
Conclusion
There was no evidence that treatment of children with
severe malaria with parenteral artemisinin derivatives was
associated with lower mortality or long-term morbidity
compared to parenteral quinine. Future studies require
adequately powered equivalence trial design to decide
whether both drugs are equally effective.
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